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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative dementia characterized by the decline of cognition
and the presence of neuropathological changes including neuronal loss, neurofibrillary pathology and extracellular
senile plaques. A neuroinflammatory process is also triggered and complement activation has been hypothesized
to have a relevant role in this local inflammatory response. C5a, a proinflammatory anaphylatoxin generated after
complement activation, exerts its chemotactic and inflammatory functions through the CD88 receptor while the
more recently discovered C5L2 receptor has been postulated to have an anti-inflammatory role. Previously, we
reported that a CD88 specific antagonist (PMX205) decreased the pathology and improved cognition in transgenic
models of AD suggesting that C5a/C5aR interaction has an important role in the progression of the disease.
Methods: The present study characterizes the expression of the two receptors for C5a in human brain with
confirmed post mortem diagnosis of vascular dementia (VD) or AD as well as age matched controls by
immunohistochemistry and Western blot analysis using several antibodies against different epitopes of the human
receptors.
Results: The CD88 and C5L2 antibodies revealed increased expression of both receptors in AD samples as
compared to age-matched controls or VD brain tissue by Western blot and immunohistochemistry, using multiple
antibodies and distinct cohorts of brain tissue. Immunostaining showed that both the C5L2 and CD88 antibodies
similarly labeled abundant neurofibrillary tangles, neuropil threads and dystrophic neurites associated with plaques
in the hippocampus and frontal cortex of AD cases. In contrast, little or no neuronal staining, tangles or dystrophic
neurites associated with plaques were observed in control or VD brains. CD88 and C5L2 receptors are associated
with both early (AT8) and mature (PHF1) neurofibrillary tangles and can be found either independently or
colocalized with each other.
Conclusions: The observed association of CD88 and C5L2 with neurofibrillary pathology suggests a common
altered pathway of degradation.
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Background
Fibrillar amyloid plaques and neurofibrillary tangles are
two characteristic lesions observed in Alzheimer’s dis-
ease (AD) brains (reviewed in [1]). In vitro studies have
demonstrated the activation of both classical and alter-
native complement pathways by fibrillar Aß [2-4]. C5a, a
fragment generated by activation of complement, is
chemotactic for glia [5]. Therefore, the association of
complement components and activation products as well
as reactive glia with fibrillar plaques and tangles [6-8] is
consistent with the hypothesis that complement activa-
tion contributes to and/or exacerbates a local inflamma-
tory reaction around plaques. The detection of C5b-9
associated with dystrophic neurites in plaques and with
tangles [9] provides further evidence of complement ac-
tivation and indicates that C5a anaphylatoxin has been
generated as well. Although there are reports of C5a
neuroprotective effects [10], increasing evidence suggests
that C5a-CD88 interaction has a detrimental effect in
neuroinflammatory diseases either directly on neurons
[11-14] or indirectly via microglia activation ([15] and
reviewed in [16] and [17]).
The classically described C5a receptor, also identified
as CD88, is a G protein-coupled, seven transmembrane-
spanning receptor, and its binding to C5a results in
intracellular calcium mobilization and activation of sev-
eral signaling pathways such as MAPK, ERK, DAG and
PI3K (for a review see [18,19]). C5L2 is a more recently
described C5a binding seven transmembrane receptor
that appears to be deficient in G protein coupling. Its
function is still not well defined although some evidence
indicates that it can be anti-inflammatory (for review see
[20]) and/or a modulator of the CD88 mediated signal
transduction through the ß arrestin pathway [21]. Ex-
pression of CD88 in the periphery has been shown to in-
clude not only myeloid but also non myeloid cells such
as endothelial and epithelial cells. C5L2 distribution is
similarly broad (reviewed in [18]). In the central nervous
system (CNS) (human, rat and mouse), CD88 receptor
protein and mRNA has been reported to be expressed in
astrocytes, microglia, subsets of neurons and neural pro-
genitor cells. While there are more limited studies of
C5L2 expression, there is evidence for message in
human brain and protein expression in rat astrocytes
and subsets of neurons (reviewed in [22]). However, the
role of either receptor in neurons is not well established
and likely to be complex depending on the environmen-
tal signals as reviewed by Woodruff and colleagues [22].
Studies with mouse models of AD also show the associ-
ation of complement factors and receptors with amyloid
plaques [23,24] demonstrating complement activation in
those models. More recently, our observation of a
neuroprotective effect of a CD88 antagonist [25] in two
mouse models of AD added support to the hypothesis that
the consequences of C5a-CD88 interactions are detrimental
in the aging brain. The effect of specific C5aR antagonists
in decreasing the pathology and improving clinical
symptoms in animal models of other neurodegenerative
diseases [26,27] suggests that C5a-CD88 interaction
accelerates disease and can be a therapeutic target. In con-
trast, there is evidence suggesting that C5L2 receptors have
an anti-inflammatory function [28-30].
Reports of the relative expression of CD88 in neurons in
AD are conflicting. O’Barr et al. observed comparable ex-
pression in neuron populations of AD and normal control
brains [12], while Farkas and colleagues reported that the
neuronal expression of CD88 is decreased in AD, although
it was seen to be present in dystrophic neurites associated
with plaques [31]. At present, there are no reports of the
C5L2 distribution in the AD brain. Here we report the ex-
pression of both C5a receptors in cases of vascular de-
mentia (VD) and AD as compared to age-matched
controls using several antibodies against different epitopes
of the receptors. These data show that CD88 and C5L2
protein levels are increased in AD and that these receptors
are associated with AD neurofibrillary pathology (neuro-
fibrillary tangles, dystrophic neurites associated with
plaques and neuropil threads).
Material and methods
Subjects
Human brain tissue, including 5 VD, 11 AD and 9 age-
matched controls, was obtained from the Tissue Reposi-
tory of the Institute for Memory Impairments and
Neurological Disorders at the University of California,
Irvine (UCI). Cases studied are shown in Table 1. Tissue
was collected within 1 to 13 hours of death and was
fixed in 4% paraformaldehyde or 10% formalin (used
for immunohistochemistry (IHC)) or frozen (used for
Western blots). This study also included 24 cases from
the Rush Religious Order Study [32] with ante mortem
clinical diagnoses of either no cognitive impairment
(NCI) (n = 12, Mini-Mental State Examination (MMSE)
Score = 27.6 +/− 1.4 (mean +/− SD)) or mild/moderate
AD (n = 12, MMSE = 19.9 +/− 6.4). The Braak tangle
stage was: NCI:3.0 +/− 1.35, AD:3.75 +/−1.14. The cases
were matched for age (total = 85.6 +/− 5.1 years) and
post mortem interval (total = 5.1 +/− 2.5 hours) [32].
Hippocampal samples from each case were dissected
and snap-frozen at −80°C until used for Western blot.
All the tissue obtained from Alzheimer Disease Centers
at UCI or Rush was acquired under approved Institu-
tional Review Board protocols.
Immunohistochemistry
Tissue sections (50 um) (three to five per case from hippo-
campus or cortex) were immunostained, as described pre-
viously [33]. Briefly, sections were pretreated with 3%
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H2O2/10% MeOH/Tris buffered saline (TBS), pH 7.4 to
block endoperoxidase. For staining with antibodies that
needed antigen retrieval pretreatment, antigen unmasking
solution was used following the manufacturer’s instructions
(Vector, Burlingame, CA, USA). After blocking with 2%
BSA/10% normal goat serum/0.3%Triton/TBS, sections
were incubated with the corresponding antibodies (Table 2)
in blocking solution, overnight at 4°C. For C5L2 staining,
the following antibodies were used: rabbit anti C5L2 N–
terminal peptide 1–23 (4 ug/ml, Hycult Biotechnology,
Uden, The Netherlands), anti C5L2 N–terminal peptide
1–50 (5 ug/ml, Abcam, Cambridge, MA, USA), anti C5L2,
aa248-311 (Abcam), and anti C5L2 C-terminal peptide (aa
275–325) (5 ug/ml, Novus Biologicals, Littleton, CO,
USA), and mouse anti C5L2 clone 4C8 (5 ug/ml, gift of
Dr. T. Woodruff, raised against human C5L2 transfected
murine pre B L1.2 cells (Bamberg et al., 2010)) and anti C5L2
clone1D9M12 (Biolegend, San Diego, CA, USA). For CD88,
rabbit anti CD88 C-terminal peptide 300–350 (5 ug/ml,
Novus), anti C-terminal peptide around phosphorylation site
(ser338) and anti CD88 N-terminal peptide (both 5 ug/ml,
Abcam), as well as the monoclonal rabbit CD88 clone C85-
2506 (BD Biosciences, San Jose, CA, USA) and mouse anti
CD88 N term1-31,clone S5/1 (Serotec, Raleigh, NC, USA)
were used. After incubation with primary antibody overnight,
sections were incubated with biotinylated anti rabbit or anti
mouse antibodies (Vector, Burlingame, CA, USA) (1 hour at
room temperature) followed by Vectastain ABC (Vector)
(1 hour at room temperature) and developed with DAB
(3-3’diaminobenzidine) substrate kit (Vector). Tissue was
dehydrated and mounted with DePeX (BHD Laboratory
Supplies, Poole England).
For immunofluorescent colocalization of the CD88 or
C5L2 receptors with markers of hyperphosphorylated
tau (AT8, PHF-1), sections were incubated first with the
anti CD88 or C5L2 antibody (overnight at 4°C), followed
by the corresponding Alexa 555 labeled anti rabbit sec-
ondary antibody (Invitrogen, Molecular Probes, Eugene,
OR, USA). After washes and a blocking step the
corresponding second primary antibody (AT8 1:50,
Table 1 List and information of cases studied
Case year Case num Age Sex MMSE PMI APOE NPDx1 NPDx2 Braak tangle stage Braak plaque stage
2003 9 81 M 27 6.4 2/3 N/MBC II 0
2006 34 79 M N/A 3.52 2/4 N/MBC Other V B
2005 32 89 F 24 3.58 3/3 N/MBC III B
2004 30 90 F 30 3.8 3/3 N/MBC Other IV B
2005 12 78 M 12 2.8 3/4 N/MBC DLBD III B
2005 13 94 F N/A 5.92 N/MBC I A
1997 27 66 M N/A 13.37 N/A N/MBC N/A N/A
1997 32 68 M N/A 2.43 N/A N/MBC N/A N/A
1999 10 70 M N/A 5.2 N/A N/MBC N/A N/A
2004 8 75 F N/A 10.5 3/3 N/MBC VD II 0
2003 4 83 M 28 12.4 4/4 N/MBC VD III 0
2002 17 74 M 14 2.6 3/4 N/MBC VD II A
2001 20 85 M 15 3.2 2/4 N/MBC VD III 0
2001 14 73 M N/A 4.3 3/3 N/MBC VD 0 0
2006 1 63 M 10 5.8 3/4 AD VI C
2006 21 82 M 16 4.7 3/4 AD VI C
2004 10 71 M 3 6.4 3/3 AD VI C
2004 44 96 F N/A 4.3 3/4 AD VI C
2004 46 94 F N/A 26.92 2/3 AD VI C
2005 31 79 M 6 6 3/4 AD VI C
2007 15 75 M 18 5.08 3/4 AD VI C
2008 3 72 M 0 8.25 4/4 AD VI C
2008 4 68 M 3 4.83 3/4 AD VI C
2001 12 61 F N/A 2.8 3/4 AD VI C
2001 18 74 F N/A 4.5 3/4 AD VI C
AD, Alzheimer’s disease; MMSE, score for the Mini Mental Status Exam; N/A, not available; N/MBC, normal mild Braak changes; NPDx1, neuropathological diagnosis;
NPDx2, secondary neuropathological diagnosis; PMI, post mortem interval in hours; VD, vascular dementia.
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Pierce, Rockford, IL, USA or PHF-1 1:1000, a gift from
Dr. P. Davies, Albert Einstein College of Medicine,
Bronx, NY) was added (overnight at 4°C) and developed
with Alexa 488 labeled anti mouse secondary antibody
(Invitrogen, Carlsbad, CA, USA). Tissue was mounted
with Vectashield (Vector).
Colocalization of CD88 and C5L2 was done by se-
quential staining using first N1-50 C5L2 antibodies
(overnight incubation) followed by Alexa555 anti rabbit
secondary antibody (1 hour, 4°C). After washing and
blocking with normal rabbit serum for 30 minutes (to
saturate possible free sites of the secondary antibody),
anti CD88 antibody (Novus C300-350), fluorescently la-
beled with fluorescein isothiocyanate (FITC) using the
Lightning link antibody labeling kit (Novus Biologicals)
following the manufacturer’s instructions, was added
and incubated overnight at 4°C.
Specificity of staining was demonstrated by a lack of
reactivity when using rabbit immunoglobulin G (IgG; at
the same concentrations as the primary antibodies) or
no antibody instead of primary antibody plus the sec-
ondary antibodies as controls. In addition, anti C5L2
(N1-23) (5 ug/ml) was preabsorbed with 100 ug/ml
C5L2 (N1-23) (United Peptide, Bethesda, MD, USA)
and then used to validate the specificity of staining in
IHC. Pictures were taken under bright field or fluores-
cence optics with Zeiss Axiovert 200 (Carl Zeiss,
Thornwood, NY, USA). Images were captured with
Zeiss Axiovision 4.6 software. Confocal images were
obtained with Zeiss LSM 510 confocal microscope. To
evaluate the extent of colocalization between pairs of
images of C5L2 (red channel) and CD88 (green chan-
nel), the Mander’s coefficient was calculated using
ImageJ software with JaCoP plugin [34]. The values
of Mander’s coefficients range from 0 to 1, with 1
indicating 100% colocalization and 0 indicating no-
colocalization.
Western Blot
Hippocampi were homogenized (10 to 12 strokes with a
glass homogenizer) in 2% SDS TBS (50 mM Tris–HCl
buffer, 150 mM NaCl, pH 7.4) (0.150 g tissue/ml),
containing a cocktail of protease inhibitors (complete
Mini) (Roche Diagnostics, Indianapolis, IN, USA).
Homogenates were centrifuged at 4°C at 15,000 g for 30
minutes. Protein concentration in the supernatants
was determined with the BCA protein assay (Pierce,
Rockford, IL, USA). Samples (40 ug protein per lane)
were run on 10% SDS polyacrylamide gel under reducing
conditions. Proteins were transferred to polyvinylidene
difluoride (PVDF, Millipore Corporation, Bedford, MA,
USA) membranes (300 mA for 2.5 hours). Membranes
were blocked with 3% dry milk in 0.1% Tween/TBS for
1 hour and then incubated for 2 hours at room
temperature with primary anti C5L2 or CD88 antibodies
(Table 2). In some cases, C5L2 N1-23 antibody (2 ug/ml)
with or without a preincubation with the blocking peptide
N1-23 peptide was used as the probe. After washing, blots
were incubated with horseradish peroxidase (HRP)-labeled
anti rabbit or anti mouse secondary antibodies (1:7500)
for 1 hour. Labeling was detected using the ECL system
(GE Healthcare, Pittsburg, PA, USA). Blots were treated
with stripping buffer (100 mM 2-mercaptoethanol,
2% SDS, 62.5 mMTris-HCl, pH 6.7) following the
manufacturer’s instructions (Amersham) (and verified to
lack any residual reactivity) and subsequently labeled with
anti CD88 antibodies (Table 2) (C terminal Abcam or C ter-
minal Novus, 2 ug/ml, or clone C85-2506, BD 1.5 ug/ml),
followed by anti rabbit HRP-labeled secondary anti-
bodies (1:7500 dilution, Jackson Immunoresearch,West
Grove, PA, USA) and detected with ECL. Finally, blots
were stripped and probed with anti ß actin antibody
(1:10,000 dilution, Sigma, St. Louis, MO, USA) followed
by anti mouse HRP-labeled secondary antibody (1:10,000
dilution, Jackson) and detected with ECL. Quantification
Table 2 Antibodies tested in the study
Antibodies Type and source IHC WB
C5L2 N 1-23 Rabbit polyclonal (Hycult) + +
C5L2 N 1-50 Rabbit polyclonal (Abcam) + +
C5L2 C-term peptide Rabbit Polyclonal (Novus) + –
C5L2 248-311 Rabbit Polyclonal (Abcam) – +
C5L2 clone 1D9M12 Mouse monoclonal (Biolegend) – +
C5L2 clone 4C8 Mouse Monoclonal (T.Woodruff) + ND
CD88 C 300-350 Rabbit polyclonal (Novus) + –
CD88 N term peptide Rabbit polyclonal (Abcam) + ND
CD88 C term peptide Rabbit polyclonal (Abcam) + +
CD88 clone C85-2506 Rabbit monoclonal (BD Pharmingen) – +
CD88 clone S5/1 N1-31 Mouse monoclonal (Serotec) – ND
IHC, immunohistochemistry; ND: not done; WB, Western blot.
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of the bands was done using Image J (National Institutes
of Health) software. Each sample was tested in two Western
blots in independent experiments. Data were analyzed using
Student t-test statistical analysis.
Alternatively, samples from the Rush Religious Orders
Study were prepared as previously reported [32]. Briefly,
frozen hippocampi were homogenized with protease
inhibitors by sonication for 10 seconds and centrifuged
at 100 g for 10 minutes at 4°C. Supernatant proteins (25
ug/sample) were separated by SDS-PAGE, transferred to
Immobilon P membranes (Millipore), blocked in TBS
(pH.7.4)/0.1% Tween-20/5% milk and incubated over-
night at 4°C with rabbit polyclonal C5L2 antise-
rum (aa248-311) (5 ug/ml Abcam #96808). Blots were
incubated for 1 hour with HRP-conjugated goat anti-
rabbit IgG. The blots were then probed overnight with
a mouse monoclonal beta-actin antibody (1:20,000;
Millipore, Billerica, MA, USA). Reactivity was quantified
using Kodak one-dimensional image analysis software
(Perkin-Elmer, Waltham, MA, USA). C5L2 protein levels
were normalized to β-actin levels in each sample. Each
sample was analyzed on three different Western blots in
independent experiments. Data were analyzed using Stu-
dent t-test. Correlation analysis between C5L2/ßactin
ratio and Braak tangle stage for UCI and Rush samples
was done using the Spearman rank test.
Results
C5L2 distribution in control, vascular dementia and
Alzheimer’s disease brain
The distribution of C5L2 receptor in the brains of control
(n = 9), AD (n = 11) and VD (n = 5) cases was assessed by
IHC using three polyclonal antibodies, two against the
extracellular N terminus of the receptor and one against
the intracellular C terminus domain. N1-23 antibody
showed a light reactivity with what appeared to be healthy
neurons (mainly pyramidal) in frontal cortex and hippo-
campus of controls (Figure 1A,B) and VD cases (data not
shown). In hippocampus of some of these cases a few
neurofibrillary tangles (NFT) were stained (data not
shown). However, in AD brain, the antibodies strongly la-
beled a subset of mainly intraneuronal NFTs in frontal cor-
tex (Figure 1C) in 9 of 11 cases, and more abundantly in
the CA area (mainly in the CA1 and CA2 subfields) of
hippocampus (Figure 1D and Additional file 1: Figure S1).
Some neuropil threads (NT) were also labeled (Figure 1D,
insert). C5L2 antibody N1-23 immunoreactivity in frontal
cortex or hippocampus was blocked by preabsorption of
the antibody with the N1-23 peptide (Figure 1E and F)
showing specificity of the anti-peptide antibody. The
antibodies against the N1-50 region of C5L2 showed
immunoreactivity in scarce dystrophic neurites associated
with plaques (DNP) in frontal cortex of some controls and
Figure 1 C5L2 is present in neurons of control brain and neurofibrillary tangles of AD brain. Immunostaining with anti C5L2 antibody
N1-23 shows labeling of a subset of neurons in frontal cortex (FC) (A) and hippocampus (B) of control cases and strong staining of tangles
(arrowheads) in frontal cortex (C) and hippocampus (D) of AD cases. Scale bar: 50 um. Arrow in insert (D) shows neuropil threads. C5L2 N1-23
antibody immunostaining in hippocampus of an AD case (E) disappears after antibody preabsorption with the peptide (F). Scale bars: A,B,C,D
(and insert): 50 um; E,F: 100 um. AD, Alzheimer’s disease.
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VD cases (Figure 2A and data not shown). In hippocampus,
these cases were either negative (Figure 2B) or showed very
few DNP or tangles labeled (Figure 2C). In contrast, in the
AD brains, similar to the N1-23 antibody, NFT and NT
were strongly immunoreactive with the N1-50 antibody
(Figure 2E, F) in hippocampus, although not in frontal
cortex. However, N1-50 abundantly stained DNP in frontal
cortex (Figure 2D) and in hippocampus (Figure 2E, and
insert).
Another antibody against the carboxy terminal region of
C5L2 (Novus), labeled DNP that were very abundant in
the AD brain compared to the control and VD cases (data
not shown), similar to the pattern of the N1-50 antibody.
In addition, this antibody showed some light neuronal
staining and reacted also with endothelial cells of blood
vessels in both controls and AD (data not shown).
Other anti C5L2 antibodies were also tested. A mono-
clonal antibody clone 4C8 [21]) showed light neuronal
staining that was similar in control and AD cases (data
not shown). No immunoreactivity was detected using
polyclonal antibody against 248–311 or clone 1D9M12
monoclonal anti C5L2 (data not shown). These data in-
dicate that the epitopes recognized by these antibodies
are not accessible in these fixed tissue samples.
The expression of C5L2 was assessed in SDS lysates
from hippocampus of the same control and AD cases
used for IHC by Western blot analysis. Both N1-23 and
N1-50 antibodies showed immunoreactivity with three
bands at 50 k, 45 k and 37 k Mr (Figure 3A and data not
shown). No other bands were observed in the blot. The
bands at 45 k Mr (expected for the native glycosylated
form of the C5L2 receptor) and 37 k Mr (expected size
of the receptor based on protein sequencing) were
stronger in all the AD cases tested than in control cases
where they were almost undetectable relative to compar-
able protein load as validated with actin labeling
(Figure 3A). Densitometric quantification of the 37 k Mr
band normalized to actin showed a statistically signifi-
cant 158% (control, n = 4; AD, n = 5; P <0.01) increase
in the AD samples (Figure 3D). The 50 k Mr band was
Figure 2 C5L2 antibodies label dystrophic neurites associated with plaques as well as neurofibrillary tangles. Representative pictures of
C5L2 staining using antibody N1-50 in FC of VD (A) and hippocampus of control (B) and VD (C) brain, and FC (D) or hippocampus of two AD
cases (E, F). Arrowhead in D shows dystrophic neurites associated with plaques in cortex (DNP). Insert in E shows DNP in hippocampus. Scale
bars: 50 um. AD, Alzheimer’s disease; FC, frontal cortex; VD, vascular dementia.
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variable among the control and AD cases with no clear
differences between the groups. Probing with irrelevant
rabbit IgG gave no such bands. Preabsorption of the C5L2
antibody with the peptide N1-23 (100 ug/ml) eliminated
completely the 37 k Mr band (Figure 3A, 3D left panel)
validating the specificity of the antibody for the peptide in
solution. The 45 k Mr band was not included in the
Western blot quantification since its reactivity was not
reduced by preabsorption with the peptide. Although the
45 k Mr band could be a glycosylated state of the receptor,
we could not confirm the specificity of that band.
These Western blot results were corroborated using
control (n = 12) and mild AD (n = 12) hippocampal
homogenates from a different source and probing with a
different anti human C5L2 antibody (anti C5L2 aa248-
311, Abcam, Table 2). Densitometric quantification of
the Western blot membranes of those samples similarly
showed a significant increase (46%, P <0.01) in the 37 k
Mr band of the AD relative to the control samples
(Figure 3C, 3D right panel). To corroborate these results
further, lysates from the UCI cases were tested with the
Abcam antibody used in the Rush cases. Similar to the
results shown in Figure 3C, only one band at 37 k Mr
was detected, further demonstrating that the 37 k Mr
band is C5L2 (Data not shown).
A Spearman correlation analysis between the C5L2/ß
actin ratio and Braak tangle stage indicated a positive
correlation for both UCI (r = 0.8, P <0.01) and Rush
cases (r = 0.4, P <0.06). In the UCI cohort the positive
correlation was strong and reached statistical signifi-
cance since all the AD cases were late stage in contrast
with the Rush cohort that included mostly mild to mod-
erate AD cases.
In summary, C5L2 receptors are mainly detected
associated with neurofibrillary pathology and are more
abundantly expressed or accumulated in AD brain cor-
relating with Braak tangle stage.
CD88 distribution in control, vascular dementia and
Alzheimer’s disease brain
The CD88 distribution in brain was studied with anti-
bodies against the C terminal intracellular (Novus) or N
terminal extracellular domains (Abcam) of the human
CD88 receptor in the same cases tested with the anti
C5L2 antibodies. Both CD88 antibodies reacted simi-
larly, labeling abundantly NFT, NT and DNP mainly in
the CA1 and CA2 area of hippocampus of AD cases
(Figure 4B, C). In frontal cortex of AD, they labeled
similar structures but they were less abundant (data not
shown). VD and control cases showed scarce NFT
staining in hippocampus (Figure 4A and data not
shown). Some light neuronal CD88 staining was also
seen in frontal cortex of a few VD and AD cases (data
not shown). The degree of immunoreactivity paralleled
the severity of the tangle pathology in the AD cases, and
was similar to the staining pattern of the C5L2 anti-
bodies (in particular the N1-50 anti C5L2) labeling
neurofibrillary pathology. As with the anti C5L2 anti-
bodies, CD88 antibodies also variably stained endothelial
cells in blood vessels in control, VD and AD brain (data
not shown and Figure 5C). Two additional anti CD88
monoclonal antibodies (clone S5/1 (Serotec) and rabbit
monoclonal (BD) showed no reactivity in these same
samples (data not shown).
Figure 3 C5L2 and CD88 expression is upregulated in AD cases.
A. Control and AD extracts from hippocampus subjected to SDS
polyacrylamide gel and transferred to PVDF membranes were
probed sequentially with anti human C5L2 antibody (N1-23 epitope)
upper lane, anti human CD88 (Abcam, C terminal epitope) (middle
lane) and anti ß actin (lower lane). B. Western blot of hippocampus
lysates of AD case probed with C5L2 N1-23 antibody with (left lane)
and without (right lane) preadsorption of the antibody with the
N1-23 peptide. The 37 k Mr band is eliminated by preadsorption.
C. Western blot of hippocampus homogenates of control and AD
cases (from the Rush Religious Order Study) using Abcam polyclonal
antibody against aa248-311of C5L2 and ß actin antibody for further
densitometric quantification. D. Densitometric quantification of C5L2
immunoblots. Bars show average of ratio of C5L2/ßActin +/− SE
from Figure 3A which are AD (n = 5) 0.31 +/−0.05 and C (n = 4)
0.12+/− 0.03, P <0.01 (left) or from Figure 3C and data not shown
AD (n = 12) 1.05+/−0.05 and C (n = 12) 0.72+/− 0.03, P <0.01 (right).
AD, Alzheimer’s disease; C, control; n, number; PVDF,
polyvinylidene difluoride.
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The expression of CD88 also was assessed by Western
blot in the same cases as the C5L2 receptor with the
Abcam anti C-terminus antibody (Figure 3A). In AD
cases the 37 K Mr band was 143% of the control (P <0.001).
While the Novus anti CD88 did not recognize the denatured
CD88 on Western blot, the BD monoclonal anti CD88 also
showed increases in the 37 K Mr band in AD cases (data
not shown, Table 2).
C5L2 and CD88 receptors colocalize with
hyperphosphorylated tau markers
Immunofluorescent double labeling of C5L2 with early
(AT8) (Figure 5A) or mature (PHF-1) (data not shown)
tangle markers confirmed co-localization of C5L2 with
phosphorylated tau in structures which morphologically
appeared to be NFTs, DNPs or NTs in frontal cortex
and hippocampus in the AD brain. Similar to C5L2,
CD88 immunoreactivity was also found in NFTs and
DNP colocalized with AT8 (Figure 5B) and PHF-1 (data
not shown). However, not all AT8 or PHF-1 positive
neurofibrillary pathology was C5L2 or CD88 positive.
C5L2 and CD88 receptors colocalize in neurofibrillary
tangles
Colocalization of C5L2 and CD88 in human brain tissue was
assessed in control, VD and AD cases. These receptors have
a low overall sequence homology of 35%. Therefore, in order
to avoid any cross reactivity, two antibodies directed against
different epitopes with even lower sequence identity were
used for double labeling: the N terminus was selected for the
C5L2 antibody (N1-50, Abcam) and the C terminus (C300-
350, Novus) for CD88. These regions of the two receptors
lacked significant overlap (24% and 26% identity respectively
for CD88 and C5L2). Confocal images showed that while the
receptors could be seen independently expressed, they
exhibited a high degree of colocalization in NFTs (Figure 5C).
Evaluation of CD88 and C5L2 receptor colocalization
resulted in a Mander’s coefficient of 0.66 which is equivalent
to 66% colocalization in the hippocampal sections analyzed.
The coexpression of the receptors was consistent with
the similar patterns of distribution and colocalization
with hyperphosphorylated tau markers described above
(Figures 1, 2 and 4).
Discussion
The two identified cell surface receptors for the comple-
ment activation peptide, C5a, designated CD88 and
C5L2, have been reported to be upregulated in mouse
models of several neurodegenerative (inflammatory)
diseases, suggesting a role in either disease pathology or
modulation or both (reviewed in [22,35]). The results
presented here show increased CD88 and C5L2 protein
expression in the brain of human AD cases as compared
with age-matched controls. CD88 and C5L2 were
associated with NFTs (mainly intraneuronal), DNPs, and
NTs in the hippocampus and frontal cortex of AD cases.
While CD88 and C5L2 were detected in the endothelial
cells lining vessel walls, CD88 and C5L2 receptors were
predominantly colocalized with both early (AT8) and
mature (PHF) tangle markers associated with degenerat-
ing neurons.
The detection of a quantitative enhancement of CD88
in AD brain differs from previous studies that showed
either similar neuronal expression of CD88 receptor be-
tween control and AD samples [12], or a decrease of the
CD88 receptor in neuron populations of AD brains
compared to controls [31]. These quantitative differences
observed in IHC studies could be attributed to differences
in tissue processing or in the epitopes recognized by the
antibodies. The antibodies in our study were raised against
an N terminus epitope similar to, but not identical with,
that used by O’Barr and colleagues [12]. In our study, the
Figure 4 CD88 immunoreactivity is also abundantly present in
neurofibrillary tangles of AD cases. Immunostaining using two
antibodies against different CD88 epitopes: Novus carboxy terminal
(A, B) and Abcam amino terminal (C) in hippocampus of VD (A) and
AD cases (B, C). Arrow and arrowhead show neuropil threads and
tangles respectively. Scale bar: 50 um. AD, Alzheimer’s disease; VD,
vascular dementia.
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results were confirmed with an antibody raised against a
C terminal CD88 epitope which showed similar staining
patterns. In addition, Western blot analysis using brain
lysates from the same cases used for IHC also showed an
overall increase in reactivity of both the CD88 37 k Mr
and 45 k Mr bands in the AD samples compared to
controls, thereby validating our IHC data.
The C5L2 receptor distribution at the protein level in
the CNS of human samples has not been previously
reported, although Northern blot analysis demonstrated
mRNA expression in human frontal cortex, hippocam-
pus, hypothalamus and pons [36]. In rat brain, C5L2 was
reported to be present constitutively in neurons and
astrocytes and also upregulated by noradrenaline correl-
ating with a hypothesized anti-inflammatory role [28]. In
a rat model of amyotrophic lateral sclerosis (ALS) C5L2
receptor was upregulated at early stages of the disease in
motor neurons [26,37] and was shown to be colocalized
with ubiquitinated intracellular aggregates which are
characteristic of ALS [37]. In the present work, C5L2
was associated with NFTs, prevalent in AD brain. Pro-
tein levels were increased in hippocampal lysates from
AD brains compared to controls. These results were
validated by utilizing two distinct cohorts of AD and
control samples as well as antibodies to two different
C5L2 epitopes. Preabsorption of the anti N1-23 antibody
with the N1-23 peptide (N-terminus of C5L2) showed a
loss of immunostaining in cortex and hippocampus and
a blockade of reactivity of the 37 k Mr band in Western
blots confirming that the reactivity detected was indeed
against C5L2.
The role of C5a receptors in neurons, microglia and
astrocytes in neuroinflammatory diseases (for review see
[22]) is not clear. Some reports have suggested that C5a
induces neuroprotective pathways in some scenarios
[12,38], and enhanced recruitment of phagocytes to
plaques could be postulated to facilitate clearance of plaques
and cell debris [25,39]. While both beneficial and detrimen-
tal roles are not mutually exclusive, support for an overrid-
ing detrimental role for CD88 has been provided by the
improvement in pathology and clinical symptoms obtained
in animals models of AD, Huntington’s disease (HD) and
ALS treated with specific antagonists for this receptor
(PMX53 and PMX205) [25-27], as well as in ischemic stroke
[11]. In murine AD models, PMX205 was effective in redu-
cing plaques, reactive glia, and improving neuronal integrity
as well as cognition [25]. While the exact mechanism is not
known, the protective effects of the antagonist could be due
to the blockade of C5a binding to CD88 in glia, although an
interaction of PMX205 with a neuronal CD88 is also pos-
sible. In the Tg2576 and Arc48 mouse models of AD, CD88
receptors were shown to be present in microglia polarized
towards plaques and were upregulated in parallel with
plaque and glia pathology [24]. The lack of glial CD88
Figure 5 C5L2 and CD88 colocalize with markers of
hyperphosphorylated tau and can be expressed in the same
neurofibrillary tangles. Confocal pictures of hippocampus of AD
cases showing colocalization of (A) C5L2 (Abcam, anti N1-50, red)
and AT8 (green), (B) CD88 (Novus anti C300-350, red) and AT8
(green), and (C) CD88 (Novus anti C300-350, green) and C5L2 (anti
N1-50 red) colocalize in tangles. Scale bar: 50 um. AD,
Alzheimer’s disease.
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detection in our study with human tissue could be due to
the differential ability of the antibodies used to detect glial
CD88 in fixed tissue and/or a lower degree of inflammation
in the human AD brain at the time of death relative to that
in the inflamed brains reported by others [40,41]
The presence of C5aR in neurons suggest their involve-
ment in functional roles that may differ from those in glia
and may also be different according to neuronal cell types
and/or stages of development. Several putative roles have
been attributed to the neuronal C5aR, such as cytoskeletal
plasticity, induction of adhesion molecules or neurotrophins
and clearance of anaphylotoxins (for reviews see [22,35,42]).
CD88 has also been proposed to have a role in the develop-
ment of cerebellum [43] and to act as a guidance cue for
granule cells [44]. In contrast, C5aR might be involved in
apoptosis in neurons (15). Recently, C5a was shown to be
generated by CNS neurons and to induce neuronal apop-
tosis upon ligation of CD88 in murine systems [11]. How-
ever, the role of CD88 and C5L2 prior to their colocalization
accumulated in NFTs (as seen in our study) is unknown.
CD88 and C5L2 have been previously shown to colocalize
in human neutrophils, with CD88 mainly expressed
extracellularly and C5L2 mainly intracellularly. After ligand
binding, the CD88 receptors were internalized, and both
(CD88 and C5L2) colocalized and associated with ß arrestin.
It was postulated that the C5L2 receptor can negatively
modulate neutrophil CD88 receptor signaling [21] reflecting
an anti-inflammatory function. C5L2 has also been
postulated to have other roles, such as decoy receptors and
could even exert a proinflammatory function (for a review
[45]). However, at the stage where both C5L2 and CD88
colocalize with NFTs, these receptors are probably in a non-
functional state.
The accumulation of the C5a receptors observed in AD
could be due to increased synthesis and/or decreased deg-
radation. TNFα, a proinflammatory cytokine released by
microglia and astrocytes [46], is increased in AD brains
[47] and has been shown to mediate the upregulation of
CD88 receptor mRNA and protein in neurons in vivo
[48]. Region specific increases in CD88 mRNA that
reached statistical significance during aging and with AD
were shown by microarray analysis of a relatively large co-
hort of young, older and AD individuals [49]. However,
the observed increased levels and association of both
CD88 and C5L2 with tangles is also consistent with a
common altered pathway of degradation. Seven trans-
membrane receptors, like CD88, recruit ß-arrestin, and,
upon internalization, the receptor and ß-arrestin are
ubiquitinated leading to degradation (reviewed in [50]). In
PHF’s, tau is also ubiquitinated [51,52]. In AD a decreased
activity of the ubiquitin proteasome system (UPS) has
been observed, and PHF-tau was shown to inhibit UPS
mediated protein degradation [53]. Thus, it is possible that
the proteasome dysfunction observed in AD can cause
tau, C5L2 and CD88 accumulation. In addition, deficits in
autophagy, another mechanism of protein clearance im-
portant for removal of aggregates and misfolded proteins,
are associated with AD [54,55]. Such defects could also
contribute to decreased turnover of CD88 and C5L2.
In summary, levels of the receptors for the comple-
ment activation fragment C5a, CD88 and C5L2 are
elevated in AD brain. Their colocalization with NFTs
suggests that this accumulation could predominantly be
a consequence of altered turnover of these receptors, ra-
ther than an increase in synthesis to contribute to, or
compensate for, an inflammatory environment. While
these findings are also consistent with a role of these
receptors in neuron degeneration, they do not rule out a
role for glial CD88 in AD pathology. Given the potential
therapeutic value of inhibiting CD88 function to prevent
or slow progression of AD as demonstrated in murine
models of AD, further study of these receptors in the
brain is warranted.
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Additional file 1: Figure S1. C5L2 immunostaining of AD brain using
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